Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Plby Group Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Plby Group Inc trades at $1 (market cap $122.20M). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 14× Plby Group Inc's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| NUVB | PLBY | |
|---|---|---|
Market Cap | $1.71B | $122.20M |
Volume | 5,448,712 | 228,361 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.54 | $2.71 |
52-Week Low | $3.41 | $0.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $1.30B | $267.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PLBY Group trades at $0.99, down 5.12% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses from -$278M in 2022 to -$13M in 2025. Positive operating cash flow of $18K in 2025 marks a turnaround from previous negative figures. Recent leadership appointments signal strategic focus on brand growth.
While analyst consensus remains bullish (75% buy ratings), high debt levels and negative shareholder equity pose significant risks. The path to sustained profitability depends on successful execution of licensing and media strategies. Near-term catalysts include Q3 2026 earnings where the company faces a $0.01 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
